Analysts have raised their price target for Doximity from $69.50 to $70.72. They cited slightly improved profit margin forecasts and increased confidence in the company’s platform engagement as advertising trends evolve.
Analyst Commentary
Recent commentary from Wall Street reflects a divided view on Doximity's outlook, with both positive and negative perspectives emerging from the latest research notes.
Bullish Takeaways- Bullish analysts are encouraged by Doximity's robust business momentum, pointing to recent earnings results that have exceeded expectations.
- The company's strategic advances in artificial intelligence, such as the launch of AI Scribe and the acquisition of Pathway AI, are seen as strengthening its platform engagement and monetization opportunities.
- Updated price targets reflect growing confidence in Doximity’s ability to adapt and capture value as digital healthcare trends evolve.
- Improved platform engagement metrics offer optimism for future revenue growth despite ongoing sector headwinds.
- Bearish analysts remain concerned about Doximity’s premium valuation compared to industry peers, suggesting the current price does not accurately reflect risks.
- Visibility into long-term growth remains limited as volatile trends in pharma digital advertising create uncertainty around future revenue streams.
- There are ongoing questions about the deceleration of pharmaceutical budgets, which could impact Doximity's advertising-related growth prospects.
- Cautious perspectives emphasize the company’s exposure to sector-wide headwinds, making sustained outperformance more challenging.
What's in the News
- Doximity repurchased 2,266,003 shares for $122.33 million in the second quarter. This brings the total completed buyback to 4,141,229 shares for $198.32 million, representing 2.21% of shares outstanding (Key Developments).
- The company issued new revenue guidance, expecting between $157 million and $158 million for the fiscal second quarter ending September 30, 2025. It is projecting full fiscal year revenue between $628 million and $636 million (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has risen slightly, moving from $69.50 to $70.72.
- Discount Rate has edged lower, decreasing from 7.89% to 7.88%.
- Revenue Growth estimate remains nearly unchanged, shifting minimally from 10.99% to 10.98%.
- Net Profit Margin projection has improved, increasing from 34.80% to 35.41%.
- Future P/E multiple is essentially flat, holding at approximately 58.8x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.